For many years, brightening formulations have focused primarily on tyrosinase inhibition. However, uneven skin tone can be influenced by several interconnected biological processes. This creates wider development requirements: formulators need multi-pathway performance, R&D teams require credible evidence, and sourcing teams must balance quality, supply reliability and cost.
Uniproma’s Tianshan Snow Lotus (W) cell-culture active has been developed to address these priorities.
Multi-pathway efficacy
In vitro testing demonstrated:
- 28.5% inhibition of melanin synthesis at 0.5%
- Reduced expression of multiple inflammatory mediators
- 17.109% average DPPH radical-scavenging rate at 5%
In vivo testing with a formulation containing 0.5% of the active demonstrated after 28 days:
- Melanin content decreased from 153.43 to 140.78
- ITA° increased from 55.02 to 55.85
- Expert-assessed skin colour score improved from 3.1 to 2.4
These findings support its use in formulations targeting brightening, radiance and uneven skin tone.
Advanced plant cell biotechnology
The ingredient combines authenticated botanical identity, standardised cultivation and HPLC-based marker analysis. This controlled plant cell platform supports batch-to-batch consistency and scalable supply while reducing dependence on wild harvesting.
The production pathway also has the potential to reduce resource consumption and the carbon footprint associated with traditional sourcing. Combined with competitive pricing, it makes advanced botanical biotechnology more commercially accessible for brands and scalable formulation development.
Tianshan Snow Lotus (W) demonstrates how botanical brightening actives can combine multi-pathway efficacy with standardised quality, sustainability and commercial viability.
